What is the optimal initial management of the older MCL patient?

Johanna C. Kluin-Nelemans*, Jeanette K. Doorduijn

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    7 Citations (Scopus)

    Abstract

    The current first line treatment of a patient with mantle cell lymphoma (MCL) is often considered as too toxic for elderly patients. The elderly, however, comprise the majority of the patients with MCL. The results of several recent studies have shown that the outcome of this patient group is not as dismal as in the past. Indeed, if patients are not considered frail, and can tolerate rituximab and moderate intensive chemotherapy such as R-CHOP followed by rituximab maintenance or R-bendamustine, a 4-year overall survival of >80% can be achieved.

    In this chapter the developments of the regimens, resulting in the standard treatment options for these patients, are discussed. (C) 2017 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)99-104
    Number of pages6
    JournalBest practice & research clinical haematology
    Volume31
    Issue number1
    DOIs
    Publication statusPublished - Mar-2018

    Keywords

    • Mantle cell lymphoma
    • Elderly patients
    • Induction therapy
    • Maintenance therapy
    • R-CHOP
    • Bendamustine
    • Cytarabine
    • Lenalidomide
    • Bortezomib
    • Toxicity
    • MANTLE-CELL LYMPHOMA
    • PROSPECTIVE RANDOMIZED-TRIAL
    • SINGLE-AGENT LENALIDOMIDE
    • PROGRESSION-FREE SURVIVAL
    • NON-HODGKINS-LYMPHOMA
    • ELDERLY-PATIENTS
    • PHASE-II
    • PLUS RITUXIMAB
    • 1ST-LINE TREATMENT
    • INDUCTION THERAPY

    Cite this